Kadcyla 160 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FCRN0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,641
Award facts
- Contract value 100% obligated
- $34,640.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,640.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 160 mg vials of Kadcyla, a specialty pharmaceutical product. Issued on December 10, 2025, with an ultimate completion date of January 2, 2026, this firm fixed-price delivery order contains no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award will be performed in Park Ridge, Illinois, and is funded by DLA's Medical Supply Chain division to support Department of Defense pharmaceutical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) within the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors. The parent IDC, designated SPE2DR, was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, structuring a 30-month base period with three 30-month option periods. DMS Pharmaceutical Group serves as a critical supplier for Department of Defense healthcare operations worldwide, distributing a comprehensive range of branded and generic pharmaceuticals, biologics, specialty drugs, and medical consumables to military healthcare facilities globally.
Quick answers
Who was awarded contract SPE2DR26FCRN0?
SPE2DR26FCRN0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 10, 2025.
How much is contract SPE2DR26FCRN0 worth?
The government has obligated $34,641 on SPE2DR26FCRN0.
Is contract SPE2DR26FCRN0 an order under another contract?
Yes. SPE2DR26FCRN0 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRN0 competed?
The extent of competition for SPE2DR26FCRN0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award